A Clinical Study on Implants With TiUltra Technology and Associated Prosthetic Components

This is a multicenter, prospective, non-interventional study in which a total of 1000 subjects in need of a single, multiple or full arch restoration in any region of the mouth (healed or extracted) will be treated in up to 30 study centers. The primary aim of this study is to demonstrate non-inferiority of all NobelBiocare TiUltra implants to historic data from NobelActive TiUnite coated implant in terms of marginal bone level change over 5 years after final prosthetic delivery. Eligible subjects who provide their informed consent for participation will be enrolled into one of four groups, each sized to 250 individuals. They will be treated with the corresponding implant system assigned to the group. The allocation into a certain group is only driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic. Each subject will be followed for 5 years after definitive prosthetic placement

Primary Objective: The primary endpoint is to evaluate the change in the marginal bone level from definitive prosthetic placement (baseline) to the 5-year follow-up visit. Secondary Objective:The secondary objectives of this clinical investigation are: * To evaluate the change in the marginal bone level from definitive prosthetic placement (baseline) to 1-year and 3-years follow-up visits * To demonstrate cumulative implant survival and success rates from definitive prosthetic placement to 5 years follow-up visit * To demonstrate cumulative prosthetic survival and success rates to 5 years follow-up visit * To evaluate soft tissue outcome (as measured by bleeding index, plaque index and gingival index) to 5 years from definitive prosthetic placement. * To evaluate SADE, USADE, ADE and DD from implant insertion until 5 years follow-up visit. Study design: This is a multicenter, prospective, non-interventional study in which a total of 1000 subjects in need of a single, multiple or full arch restoration in any region of the mouth (healed or extracted) will be treated in up to 30 study centers. The study devices are divided into four groups: * Group 1 (G1): NobelActive TiUltra implants (3.0, NP, RP, WP) * Group 2 (G2): NobelParallel CC TiUltra implants (NP, RP; WP) * Group 3 (G3): NobelReplace CC TiUltra implants (NP, RP) * Group 4 (G4): Nobel Biocare N1 TiUltra TCC implants (NP, RP) Subjects will be consecutively included provided they meet all of the inclusion criteria and none of the exclusion criteria. Eligible subjects who provide their informed consent for participation will be enrolled into one of four groups, each sized to 250 individuals. They will be treated with the corresponding implant system assigned to the group. The allocation into a certain group is only driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic. Each subject will be followed for 5 years after definitive prosthetic placement . Possible dropouts and withdrawals, as well as possible serious adverse (device) events, will be carefully monitored during the entire study period Sequence of treatment: As part of the screening process each subject will undergo a pre-treatment standard of care examination to record demographic characteristics and medical history. The subjects will be informed of the treatment possibilities according to clinic standard of care and about the study. Depending on the clinical indication, clinician preferences and desired esthetic solution the subject will be enrolled into one of the four previously described groups (G1 to G4). Implant surgery-, bone and tissue regenerative- and prosthodontic procedures shall be performed according to IFU and standard of care. Implants may be placed in either healed or extraction sites utilizing one-stage or two-stage surgical protocol with immediate, early or delayed loading to restore single missing tooth, partial or fully edentulous jaws. The treating cl trial.show_full_description

Inclusion Criteria: * Subject signed the informed consent * Subject is between 18 and 70 years of age * Subjects presented with the need of single, multiple or full arch implant rehabilitation in any region of the mouth. * Subject with medical and anatomical conditions that are in accordance with the applicable instructions for use (IFU). * Subject with sufficient bone volume for implant placement. * Subject is compliant with good oral hygiene as judged by the clinician. Exclusion Criteria: * Anatomical conditions discovered during surgery preventing the use of intended implant system. * Subjects with history of allergy or adverse reactions to any materials used * Uncontrolled diabetes (subjects with history of diabetes mismanagement and/or known A1c level above 8%)\* * Heavy smokers (\>10 cigarettes per day) * Severe bruxism or dysfunctional tendencies * Previous oro-maxillo facial radiotheraphy * Any ongoing application of interfering medication (steroid therapy, bisphosphonate, etc) * Any disorders in the planned implant area such as previous tumors, chronic bone disease or previous radiation. * Acute, untreated periodontitis in the planned implantation site or adjacent tissue. * Infections in the planned implantation site or adjacent tissue. * Documented complete remission of \>3 years if history of non-oral cancer. * Pregnant or lactating women at the time of implant insertion. \*Assessment of A1C level is not required unless it is standard of care at the treating clinic